Reproxalap was found to be safe to take in patients diagnosed with dry eye disease (DED), as no serious treatment-emergent adverse events (TEAEs) were reported in patients taking the medication. These ...

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer ...

Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap. Glucagon-like peptide-1 ...

Genome-first analyses in UK Biobank and All of Us support RBM20 as an arrhythmogenic DCM gene, with an etiologic fraction of ...

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. Leader said many large cancer centers are working more ...

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

An Excel-based actuarial model (1 million lives; 49% eligible; 10% treated) estimated semaglutide coverage could be ...

Environmental triggers were reported by 69.4% of patients, most commonly water/handwashing, chemical irritants, contact ...

Sparsentan received full FDA approval for FSGS in patients aged 8–75 years, addressing a rare, progressive glomerulopathy ...

The mCRPC section's reorganization by prior treatment exposure reflects how ARPI and docetaxel use in the hormone-sensitive ...

As HIV care continues to evolve, 2-drug regimens are emerging as a key strategy to balance efficacy with long-term ...

Real-world persistence data for tildrakizumab paint an encouraging picture of long-term treatment durability, with ...